Difference between revisions of "Pentraxin 2 (PRM-151)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
m |
||
| Line 9: | Line 9: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Myelofibrosis medications]] | [[Category:Myelofibrosis medications]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
| + | [[Category:Stub]] | ||
Revision as of 23:26, 23 February 2021
General information
Class/mechanism per NCI Drug Dictionary: A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, recombinant human serum amyloid P/pentraxin 2 (PRM-151) may inhibit myofibroblast generation by preventing the differentiation of circulating monocytes into fibrocytes and profibrotic macrophages. PTX2 is a circulating plasma protein that belongs to the class of pattern recognition receptors (PRR) of the innate immune system.
Route: IV
Extravasation: n/a